What This Means
This research examined whether body weight status among people who have both type 2 diabetes and a liver condition called metabolic dysfunction-associated steatotic liver disease (MASLD) affects their risk of developing severe cardiovascular-kidney-metabolic (CKM) syndrome — a condition involving interconnected problems with the heart, kidneys, and metabolism. The study divided 705 hospitalized patients into two groups based on BMI: 'lean' (lower body weight) and 'non-lean' (higher body weight), and found that about 1 in 4 patients fell into the lean category. The non-lean group had notably higher rates of heart events (21.3% vs. 10.1%), brain-related vascular events (18.0% vs. 12.2%), and the most severe stage of CKM syndrome (33.5% vs. 18.6%). Statistical analysis showed that being in the non-lean group was associated with more than 2.5 times the odds of having advanced CKM syndrome.
This research suggests that among people with type 2 diabetes and fatty liver disease, those who are overweight or obese face a substantially greater burden of severe, multi-organ disease affecting the heart, blood vessels, and kidneys. The non-lean group also had more visceral (abdominal) fat and greater insulin resistance, which may help explain why this group fares worse. Interestingly, both groups had similar levels of liver scarring (fibrosis), suggesting that excess body weight adds disease risk beyond what liver disease alone can account for.
The findings highlight that body weight classification in people with type 2 diabetes and fatty liver disease may be clinically meaningful when assessing overall cardiometabolic risk. This research suggests that the combination of excess weight, fatty liver, and diabetes may create a particularly high-risk profile for severe multi-system disease, though the cross-sectional design of the study means it cannot establish that non-lean status directly causes worse outcomes.